文摘
摘要目的:比较的特点secondary-progressive (spm)和复发缓和名RRMS患者。
背景:患者的临床病程不同亚型女士是不同的。女士Corrona注册中心与国家多发性硬化症协会合作研究现实世界的疾病负担和安全/ MS疾病修饰治疗(儿童)的有效性。
设计/方法:Corrona女士是美国多中心观察注册表。手段和招生的比例spm和名RRMS使用两两之间的访问特点比较统计比较。
结果:1/22/19,557名RRMS和80 spm患者登记。spm和名RRMS患者年龄(57.0,48.6年,p < 0.0001),女性较少(68.8%,76.4%,p = 0.1351),疾病持续时间较长(19.9、12.1年,p < 0.0001),和更频繁地评为恶化/不改善当前DMT (50.1%、62.5%、45.7%、58.0%)。功能系统影响spm和名RRMS锥体(86.2%,51.5%,p < 0.0001);感官(71.8%,71.2%),肠/膀胱(62.5%,39.9%)、小脑(50.0%,39.5%)和脑(41.2%,34.5%)。意味着赶紧复发在之前的12个月为0.3。spm意味着25-foot-walk较高(11.4,6.2秒,p = 0.0001)和9洞高尔夫挂钩测试时间(32.3,23.7秒,p = 0.0001)和较低的符号数字形态测试成绩(39.4,48.9,p = 0.0001)。病人确定疾病的步骤(广泛性成长障碍)类别,3.8%比40.0%没有残疾,6.2%和22.7%,5.0%和9.2%和16.2%和12.4%有轻度,中度和无助的步态障碍,分别。68.7%比15.6%相当于广泛性成长障碍得分≥6.0规模扩大残疾状况。规模指的是生理和心理的影响女士量表之得分分别为44.2和24.1 (p < 0.0001)和32.4和28.0 (p = 0.1282)。17.5%比62.0%了(p < 0.0001)。
结论:spm和名RRMS患者在年龄女士Corrona展示重要的差异,疾病持续时间、功能系统参与,疾病的措施,就业状况和患者/医生DMT响应的印象。Corrona女士可以探索亚型之间的表型差异,如活跃的和不活跃的spm。
披露:坎特博士已经收到个人赔偿咨询,担任科学顾问委员会说,或与咨询费和/或其他活动费用non-CME服务(AbbVie Actelion股价,拜耳,生原体,Celgene公司,Corrona, EMD Serono,基因泰克,Mylan,诺华公司和赛诺菲安万特). .坎特博士收到研究资助的研究支持(Actelion股价). .Bebo博士没有披露。是的,Alexion谐调,拜耳,MA, Inc ., Celgene公司公司Genentech /罗氏,Genzyme /赛诺菲、葛兰素史克、诺华制药公司Serono, TG疗法是的;Actelion股价,Alkermes公司Corrona LLD,基因泰克/罗氏,MedDay,研究所,诺华制药公司,PCORIReceived咨询费,演讲者的局和咨询工作从生原体,Celgene公司,Chugai, EMD Serono,通用/罗氏,MedDay,诺华赛诺菲,Genzyme, Teva,和TG治疗收到生原体感染研究,Celgene公司,Chugai, EMD Serono,通用/罗氏,MedDay,诺华赛诺菲,Genzyme Teva, TG Therapeutics.Dr。Bermel已收到个人赔偿咨询、担任科学顾问委员会说,与生原体或其他活动,Genzyme,基因泰克,诺华。Bermel博士已经收到版税、许可费或合同权利支付知识产权的多发性硬化性能测试,目前注册的建筑健康和生原体。Bermel博士已经收到了从生原体研究支持,基因泰克,诺华。格林伯格博士已经收到个人赔偿咨询、担任科学顾问委员会说,或其他活动Corrona LLC.Dr。 Malley has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Employee of Corrona, LLC.. Dr. McLean has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Corrona, LLC. Dr. Rebello has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Corrona, LLC. Dr. LaRocca has nothing to disclose. Dr. Miller has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Accordant Health Services (Caremark), Adamas, BiogenIdec, Celgene, Corrona, EMD Serono, Genzyme/Sanofi, Mallinckrodt, Mapi-Pharma, Novartis, and Roche/Genentech. Dr. Miller has received research support from BiogenIdec, Mallinckrodt (Questcor), Novartis, Roche/Genentech, and MedDay.
